Figure S1. Dovitinib only dose not stimulates the induction of ALP in C2C12 cells.

(A) The effect of dovitinib on osteoblast differentiation was detected by visualizing the induction of ALP in C2C12 cells. Scale bars represent 100 µm. (B) The activity of ALP, when cells were treated with BMP-2 alone or dovitinib only, was measured by a microplate reader. All experiments were performed in triplicate.
Figure S2. The phosphorylation levels of MAPK ERK1/2 and p38 and Smad1/5/8 in dovitinib only conditions.

(A) The C2C12 cells were treated with BMP-2 (50 ng/ml) or dovitinib for 10 minutes. (B) The C2C12 cells were treated with BMP-2 (50 ng/ml) or dovitinib for 2 days. The phosphorylation of ERK1/2 and p38 and Smad1/5/8 was measured by Western blot analysis. Actin was used as a loading control.
Figure S3. Dovitinib does not enhance BMP-2-induced transcriptional activity of Runx2.

The C2C12 cells were treated with BMP-2 (50 ng/ml) alone or combined with dovitinib in culture media containing 5% FBS for 72 h. The mRNA expression level of Runx2 was measured by qRT-PCR analysis, with GAPDH used as an internal control. Detailed experimental procedures are described in the Materials and Methods.